Promising molecular targets in ovarian cancer

Current Opinion in Oncology

Volumn 21, Issue 5, 2009, Pages 412-419

  Blagden, Sarah ^a   Gabra, Hani ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Ovarian cancer; Poly (ADP ribose) polymerase inhibitors; Targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AP 23846; AVE 005; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; LY 29002; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; DNA REPAIR; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTESTINE PERFORATION; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69549083525     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832eab1f     Document Type: Review

References (78)

1. Office for National Statistics. Mortality statistics cause: review of the Registrar General on deaths by cause, sex and age, England and Wales. 2005; 32 (series DH2):275.
2. Berrino F, De Angelis R, Sant M, et al., EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 2007; 8:773-783.
3. CRUK. Ovarian Cancer Mortality Statistics. http://info.cancerresearchuk. org/cancerstats.
4. Blagden S, Gabra H. Future directions in the management of epithelial ovarian cancer. Future Oncol 2008; 4:403-411. A review summarizing 'personalized chemotherapy' in the treatment of rare ovarian histologies
5. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008; 5:577-587.
6. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689. (Pubitemid 120031871)
7. Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005; 26:1651-1656. (Pubitemid 41487980)
8. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25:5854-5863. (Pubitemid 44453441)
9. Katiyar P, Ma Y, Fan S, et al. Regulation of progesterone receptor signaling by BRCA1 in mammary cancer. Nucl Recept Signal 2006; 4:e006.
10. Gilmore PM, Quinn JE, Mullan PB, et al. BRCA1 regulates the interferon γ-mediated apoptotic response. Biochem Soc Trans 2003; 31 (Pt 1):257-262.
11. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14:927-939. (Pubitemid 30253002)
12. Nagaraju G, Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair (Amst) 2007; 6:1018-1031. (Pubitemid 46880481)
13. Carreira A, Hilario J, Amitani I, et al. The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 2009; 136:1032-1043.
14. Quinn JE, Carser JE, James CR, et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113:134-142. A paper summarizing research into BRCA1 status (in ovarian cancer) as a means of predicting response to standard chemotherapy.
15. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 2009; 89:23-40.
16. Yap TA, Boss DS, Fong PC, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers [abstract #3529]. J Clin Oncol 2007; 25 (18S).
17. Fong PC, Boss DS, Carden CP, et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study [abstract #5510]. J Clin Oncol 2008; 26 (15S). The first phase I trial exploring use of PARP inhibition in patients with ovarian cancer and BRCA deficiency.
18. Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002; 94:990-1000. (Pubitemid 34814728)
19. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-819.
20. Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60:5329-5333. (Pubitemid 30761235)
21. Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003; 3:417-420. (Pubitemid 38340287)
22. Tan DS, Rothermundt C, Thomas K, et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26:5530-5536. This study explores the features of ovarian cancer in BRCA carriers, alongside their clinical characteristics.
23. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-364. (Pubitemid 26272076)
24. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8:579-591. A comprehensive review covering the use VEGF inhibitors in cancer treatment.
25. + macrophages in advanced ovarian cancer. Cancer Res 2008; 68:1100-1109. This study links ascites development in the OVCA mouse model to macrophage-activated lymphangiogenesis and the VEGF pathway.
26. Shinohara H. Lymphatic system of the mouse diaphragm: morphology and function of the lymphatic sieve. Anat Rec 1997; 249:6-15. (Pubitemid 27391414)
27. Hong YK, Shin JW, Detmar M. Development of the lymphatic vascular system: a mystery unravels. Dev Dyn 2004; 231:462-473. (Pubitemid 39410881)
28. Oliver G, Srinivasan RS. Lymphatic vasculature development: current concepts. Ann N Y Acad Sci 2008; 1131:75-81. (Pubitemid 351758504)
29. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998; 153:1249-1256. (Pubitemid 28465848)
30. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-5171. (Pubitemid 350237599)
31. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-5186. (Pubitemid 350232248)
32. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 Suppl 16):117-124.
33. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434. (Pubitemid 36910021)
34. Kaye SB. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Onco 2007; 25:5150-5152.
35. Colombo N, Mangili G, Mammoliti S, et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study [abstract #14598]. J Clin Oncol 2008; 26 (15S).
36. Biagi JJ, Oza AM,Grimshaw R, et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: NCIC CTG IND 185 [abstract #5522]. J Clin Oncol 2008; 26 (15S).
37. Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract #5537]. J Clin Oncol 2008; 26.
38. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial [abstract #5521]. J Clin Oncol 2008; 26.
39. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study [abstract #5561]. J Clin Oncol 2007; 25 (18S).
40. Trinh XB, Tjalma WA, Vermeulen PB, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009; 100:971-978.
41. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001; 98:10983-10985. (Pubitemid 32928669)
42. Altomare DA, Wang HQ, Skele KL, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23:5853-5857.
43. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448:439-444. (Pubitemid 47123510)
44. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000; 19:2324-2330. (Pubitemid 30307208)
45. Nakayama K, Nakayama N, Kurman RJ, et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006; 5:779-785. (Pubitemid 44775134)
46. Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008; 122:534-546. (Pubitemid 350308944)
47. Xing H, Weng D, Chen G, et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008; 261:108-119. Here, the antiapoptotic activity of AKT2 was demonstrated in ovarian cancer cell lines and the therapeutic strategy of AKT inhibition as a means of overcoming docetaxel resistance was discussed. (Pubitemid 351192224)
48. Yap TA, Garrett MD, Walton MI, et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8:393-412. A comprehensive review of agents targeting this pathway.
49. Nakayama N, Nakayama K, Yeasmin S, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 2008; 99:2020-2028.
50. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2007; 2:e1279.
51. Kigawa J, Kawaguchi W, Itamochi H, et al. Effect of simultaneous inhibition of MEK and PI3K/Akt pathways on paclitaxel sensitivity in ovarian cancer [abstract #16046]. J Clin Oncol 2007; 25 (18S).
52. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008; 1785:232-265.
53. Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007; 109:1323-1330. (Pubitemid 46466559)
54. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15:785-792. (Pubitemid 41783082)
55. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731-3737. (Pubitemid 46955138)
56. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063. (Pubitemid 30305105)
57. Mavroudis D, Efstathiou E, Polyzos A, et al. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC) [abstract #5020]. J Clin Oncol 2004; 22 (14S).
58. Pautier P. Preliminary results: phase II study of gefitinib in combination with paclitaxel and carboplatin as second-line therapy for advanced ovarian adenocarcinoma. ESMO 2004:A476.
59. Lacroix L, Pautier P, Duvillard P, et al. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations. Int J Cancer 2006; 118:1068-1069. (Pubitemid 43157690)
60. Vasey PA, Gore M, Wilson R, et al., Scottish Gynaecological Cancer Trials Group. Aphase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 2008; 98:1774-1780.
61. Bast RC Jr, Pusztai L, Kerns BJ, et al. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 1998; 17:313-321. (Pubitemid 28462613)
62. Bartlett JM, Langdon SP, Simpson BJ, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996; 73:301-306. (Pubitemid 26047507)
63. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:283-290. (Pubitemid 46606157)
64. Kimball KJ, Numnum TM, Kirby TO, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008; 111:95-101.
65. Schilder RJ, Pathak HB, Lokshin AE, et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009; 113:21-27.
66. Konner J, Schilder RJ, DeRosa FA, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008; 110:140-145.
67. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy [abstract #1026]. J Clin Oncol 2008; 26 (15S).
68. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24:4324-4332. (Pubitemid 46630791)
69. Kaye SB, Poole CJ, Bidzinksi M, et al. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer [abstract #5520]. J Clin Oncol 2008; 26 (15S).
70. Makhija S, Glenn D, Ueland F, et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer [abstract #5507]. J Clin Oncol 2007; 25 (18S).
71. Amler L, Makhija S, Januario T, et al. HER pathway gene expression analysis in a phase II study of pertuzumab+gemcitabine vs. gemcitabine+placebo in patients with platinum-resistant epithelial ovarian cancer [abstract #5552]. J Clin Oncol 2008; 26 (15S). This study explored the prognostic value of low HER3 gene expression as a marker of pertuzumab response in platinum-resistant patients.
72. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88:73-79.
73. Wiener JR, Nakano K, Kruzelock RP, et al. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999; 5:2164-2170. (Pubitemid 29399273)
74. Pengetnze Y, Steed M, Roby KF, et al. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003; 309:377-383. (Pubitemid 37025902)
75. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006; 66:8633-8639.
76. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009; 59:111-137.
77. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multiarm, multistage randomized controlled trial. BJU Int 2009; 103:464-469.
78. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007; 34:1339-1347. (Pubitemid 47312585)